Posts from October 2018.

The popularity of cannabidiol (CBD) products is skyrocketing as a large number of states loosen their grip on the sale of such cannabis-derived products (CBD is a non-psychoactive component of the Cannabis sativa L. plant). Additionally, the DEA’s recent decision to reschedule certain FDA-approved, cannabis-derived CBD drugs, which includes only the drug Epidiolex at current, has many under the false impression that CBD is now completely legal on the federal level. But this is not yet the case. And unfortunately, this false impression could lead to disastrous consequences for ...

Welcome to the Cannabis Business Legal News blog where attorneys from Amundsen Davis blog about all things cannabis business and legal news related. 



Recent Posts



Jump to Page

This website uses cookies. We use cookies to improve user experience, functionality, and site performance. We do not and will not sell your personal information. If you choose to continue browsing, you consent to the use of cookies. You can read more about our Cookie Policy in our Data Privacy Policy.